phoslactomycin B: structure given in first source; isolated from Streptomyces nigrescens SC-273 [MeSH]
Phoslactomycin B : no description available [CHeBI]
| ID Source | ID |
|---|---|
| PubMed CID | 11497184 |
| CHEBI ID | 80042 |
| MeSH ID | M0167943 |
| Synonym |
|---|
| 122856-26-2 |
| phoslactomycin b |
| CHEBI:80042 |
| [(1e,3r,4r,6r,7z,9z)-3-(2-aminoethyl)-10-cyclohexyl-1-[(2s,3s)-3-ethyl-6-oxo-2,3-dihydropyran-2-yl]-3,6-dihydroxydeca-1,7,9-trien-4-yl] dihydrogen phosphate |
| Q27149191 |
| DTXSID401100396 |
| Class | Description |
|---|---|
| 2-pyranones | A pyranone based on the structure of 2H-pyran-2-one and its substituted derivatives. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (76.92) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (7.69%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 12 (92.31%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| quinuclidines | quinuclidines; saturated organic heterobicyclic parent | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | ||
| alkenes | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |||
| caprylates | fatty acid anion 8:0; straight-chain saturated fatty acid anion | human metabolite; Saccharomyces cerevisiae metabolite | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| phosphazomycin c1 | 1989 | 2020 | 24.7 | high | 0 | 2 | 0 | 0 | 1 | 0 | |||
| phoslactomycin a | 1989 | 1989 | 35.0 | high | 0 | 2 | 0 | 0 | 0 | 0 | |||
| fostriecin | 2-pyranones; olefinic compound; phosphate monoester; polyketide; primary allylic alcohol; secondary allylic alcohol; triol | antineoplastic agent; apoptosis inhibitor; bacterial metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; topoisomerase II inhibitor | 2009 | 2009 | 15.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | |
| chiniofon | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |||
| beta-isocupreidine | 2009 | 2009 | 15.0 | high | 0 | 0 | 0 | 1 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|